MONEY

UCB Announces a Head-to-Head Study Evaluating BIMZELX ® (bimekizumab) versus SKYRIZI ® (risankizumab) in Active Psoriatic Arthritis

Tomas Kauer - ModeratorTomas Kauer - Moderator
Sep 30, 2024 - 20:00
UCB Announces a Head-to-Head Study Evaluating BIMZELX ® (bimekizumab) versus SKYRIZI ® (risankizumab) in Active Psoriatic Arthritis
Read More

Tags:

Previous Article

Perimeter Medical Imaging AI Announces Closing of Non-Brokered Private Placement

Next Article

China stocks surge on stimulus optimism, world stocks off record highs

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Tomas Kauer - Moderator
Tomas Kauer - Moderator

Related Posts

Hezbollah strikes Israel on Gaza war anniversary; fears grow over Middle East instability

Hezbollah strikes Israel on Gaza war anniversary; fears...

Tomas Kauer - Mode... Oct 7, 2024

Israel reinforces military presence in Lebanon after Iran attack

Israel reinforces military presence in Lebanon after Ir...

Tomas Kauer - Mode... Oct 2, 2024

Torrid Holdings executive sells over $715k in company stock

Torrid Holdings executive sells over $715k in company s...

Tomas Kauer - Mode... Sep 14, 2024